GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seer Inc (NAS:SEER) » Definitions » Cash Conversion Cycle

Seer (SEER) Cash Conversion Cycle : 300.54 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Seer Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Seer's Days Sales Outstanding for the three months ended in Mar. 2024 was 130.19.
Seer's Days Inventory for the three months ended in Mar. 2024 was 275.62.
Seer's Days Payable for the three months ended in Mar. 2024 was 105.27.
Therefore, Seer's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 300.54.


Seer Cash Conversion Cycle Historical Data

The historical data trend for Seer's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seer Cash Conversion Cycle Chart

Seer Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial - - 73.64 147.18 236.25

Seer Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 209.55 168.19 198.68 236.11 300.54

Competitive Comparison of Seer's Cash Conversion Cycle

For the Biotechnology subindustry, Seer's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seer's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seer's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Seer's Cash Conversion Cycle falls into.



Seer Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Seer's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=109.94+204.05-77.74
=236.25

Seer's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=130.19+275.62-105.27
=300.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Seer  (NAS:SEER) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Seer Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Seer's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Seer (SEER) Business Description

Traded in Other Exchanges
N/A
Address
3800 Bridge Parkway, Suite 102, Redwood City, CA, USA, 94065
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.
Executives
Elona Esq. Kogan officer: General Counsel and Secretary C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omid Farokhzad director, 10 percent owner, officer: CEO and Chair of the Board C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Scott D Thomas officer: Chief Commercial Officer C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
David R. Horn officer: Chief Financial Officer 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omead Ostadan director, officer: President & COO C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Meeta Gulyani director C/O SEER, INC., 3800 BRIDGEPOINT PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Rachel E. Haurwitz director C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Maverick Ventures Investment Fund, L.p. director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Capital Ventures, Llc director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Advisors Fund, L.p. director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
David Hallal director C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Terrance Mcguire director C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
David B Singer director C/O MAVERICK CAPITAL, LTD., 101 CALIFORNIA STREET, SUITE 4015, SAN FRANCISCO CA 94111
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005